Charles River Laboratories International (NYSE:CRL) Now Covered by Barclays

Barclays initiated coverage on shares of Charles River Laboratories International (NYSE:CRL) in a report released on Friday morning, Benzinga reports. The brokerage issued an equal weight rating and a $230.00 price objective on the medical research company’s stock.

A number of other equities analysts have also recently commented on the stock. Argus reaffirmed a hold rating on shares of Charles River Laboratories International in a research note on Friday. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating for the company in a report on Friday, May 10th. Mizuho initiated coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a neutral rating and a $235.00 price objective for the company. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating for the company in a report on Monday, May 13th. Finally, StockNews.com lowered shares of Charles River Laboratories International from a buy rating to a hold rating in a report on Friday, June 14th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of Hold and an average target price of $254.50.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $203.08 on Friday. Charles River Laboratories International has a 52 week low of $161.65 and a 52 week high of $275.00. The stock has a market capitalization of $10.46 billion, a P/E ratio of 23.89, a PEG ratio of 1.95 and a beta of 1.38. The firm has a fifty day simple moving average of $219.57 and a two-hundred day simple moving average of $232.55. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. On average, analysts expect that Charles River Laboratories International will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently bought and sold shares of CRL. Norges Bank purchased a new stake in Charles River Laboratories International during the 4th quarter worth approximately $101,319,000. Point72 Asset Management L.P. boosted its holdings in shares of Charles River Laboratories International by 499.1% in the 4th quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock valued at $87,228,000 after acquiring an additional 307,398 shares during the last quarter. Meritage Group LP boosted its holdings in shares of Charles River Laboratories International by 30.8% in the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock valued at $273,131,000 after acquiring an additional 271,743 shares during the last quarter. Epoch Investment Partners Inc. boosted its holdings in shares of Charles River Laboratories International by 2,733.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after acquiring an additional 238,766 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Charles River Laboratories International by 5,003.9% in the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock valued at $50,977,000 after acquiring an additional 211,414 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).